Dr Mark Kris highlights a recent study on osimertinib in NSCLC and outlines the best approaches for treatment beyond progression.
Prognostic effects of co-occurring TP53 and KRAS aberrations in patients with advanced biliary tract cancer.
Imlunestrant improved PFS in ESR1-mutated breast cancer compared to standard endocrine therapy, but not significantly in the overall population. Combining imlunestrant with Verzenio enhanced PFS in ...
image: Mafalda Oliveira, Senior Consultant at the Vall d’Hebron University Hospital’s Medical Oncology Department and Clinical Investigator of the Vall d’Hebron Institute of Oncology’s (VHIO) Breast ...
—Using multimodal imaging, this 10-year prospective cohort study identified markers that could help stratify patients at high risk of progressing to advanced AMD, which may help inform clinical ...
– Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, in a post-CDK inhibitor setting, compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results